Supplementary Table S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring

2026 Open access

Read full text

Authors: Jiayao Ni, Yi Sun, Hao Cheng, Xinyuan Bai, Fan Tong, Xing Zhang, Xiaoxuan Wang, Liang Mao, Gang Li, Shanshan Shen, Weiwei Kong, Jian He

+12 more

Aimei Li, Jun Chen, Min Tang, Bozhu Chen, Qi Li, Qing Gu, Zhongyu Lu, Dongsheng Chen, Huizi Sha, Baorui Liu, Yudong Qiu, Juan Du

DOI: 10.1158/1078-0432.31248746

Cited by: 0

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Breast Cancer Treatment Studies Prostate Cancer Diagnosis and Treatment